Teva’s New Global Specialty Medicines Unit To Be Led By Koremans
This article was originally published in The Pink Sheet Daily
Executive Summary
Brought in from Sanofi in 2012 as president and CEO of Teva Europe, Rob Koremans now will head a new Global Specialty Medicines unit that CEO Jeremy Levin expects to complement Teva’s generics business. Levin spoke of establishing a “single, differentiated Teva presence” in each market through the two units working together.
You may also be interested in...
A New Regime Takes The Reins At Teva
New CEO Kare Schultz has established a new leadership team and structure at the generic drug giant, as head of R&D Michael Hayden, Global Specialty Medicines CEO Rob Koremans and Global Generics Medicines CEO Dipankar Bhattacharjee will all leave at the end of the year.
A New Regime Takes The Reins At Teva
New CEO Kare Schultz has established a new leadership team and structure at the generic drug giant, as head of R&D Michael Hayden, Global Specialty Medicines CEO Rob Koremans and Global Generics Medicines CEO Dipankar Bhattacharjee will all leave at the end of the year.
EU Experts Want One-Stop-Shop EU Governance That Mimics Best Of Other Jurisdictions
It may be blue sky thinking to surmise how a new EU medtech regulatory governance structure could evolve. But with change on the horizon, experts see exciting opportunities.